We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response (SVR) could be ...